Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, via Mangiagalli 25, I-20133 Milano, Italy.
Department of Drug Design and Pharmacology, University of Copenhagen, DK-2100 Copenhagen, Denmark.
J Med Chem. 2022 Jul 28;65(14):10079-10097. doi: 10.1021/acs.jmedchem.2c00746. Epub 2022 Jul 14.
Nicotinic acetylcholine receptors containing α9 subunits (α9*-nAChRs) are potential druggable targets arousing great interest for pain treatment alternative to opioids. Nonpeptidic small molecules selectively acting as α9*-nAChRs antagonists still remain an unattained goal. Here, through modifications of the cationic head and the ethylene linker, we have converted the 2-triethylammonium ethyl ether of 4-stilbenol (MG624), a well-known α7- and α9*-nAChRs antagonist, into some selective antagonists of human α9*-nAChR. Among these, the compound with cyclohexyldimethylammonium head () stands out for having no α7-nAChR agonist or antagonist effect along with very low affinity at both α7- and α3β4-nAChRs. At supra-micromolar concentrations, and the other selective α9* antagonists behaved as partial agonists at α9*-nAChRs with a very brief response, followed by rebound current once the application is stopped and the channel is disengaged. The small or null postapplication activity of ACh seems to be related to the slow recovery of the rebound current.
含有α9 亚基的烟碱型乙酰胆碱受体(α9*-nAChRs)是一种有潜力的药物靶点,可作为阿片类药物治疗疼痛的替代品,引起了极大的关注。非肽小分子选择性地作为α9*-nAChRs 拮抗剂仍然是一个未实现的目标。在这里,我们通过修饰正离子头部和亚乙基连接基,将 4-二苯乙烯基-2-三乙铵乙基醚(MG624)转化为一些人α9*-nAChR 的选择性拮抗剂。在这些化合物中,环己基二甲基铵头部的化合物()尤为突出,它对α7-nAChR 没有激动剂或拮抗剂作用,对α7-和α3β4-nAChRs 的亲和力也非常低。在超微摩尔浓度下,和其他选择性的α9拮抗剂在α9-nAChRs 上表现为部分激动剂,其反应非常短暂,一旦停止应用并使通道脱离,就会出现反弹电流。应用后 ACh 的小或无活性似乎与反弹电流的缓慢恢复有关。